Deciphera Pharmaceuticals, Inc. (DCPH)

Market Cap	1.06B
Revenue (ttm)	121.89M
Net Income (ttm)	-221.39M
Shares Out	78.21M
EPS (ttm)	-4.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,258,554
Open	15.63
Previous Close	15.65
Day's Range	14.73 - 15.63
52-Week Range	6.51 - 20.88
Beta	0.77
Analysts	Buy
Price Target	19.02 (+26.6%)
Earnings Date	Nov 3, 2022

About DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switc...

• Industry: Biotechnology
• IPO Date: Sep 28, 2017
• CEO: Steven Hoerter
• Employees: 280
• Stock Exchange: NASDAQ
• Ticker Symbol: DCPH

Financial Performance

In 2021, DCPH's revenue was $96.15 million, an increase of 128.45% compared to the previous year's $42.09 million. Losses were -$299.96 million, 12.6% more than in 2020.

Analyst Forecast

According to 17 analysts, the average rating for DCPH stock is "Buy." The 12-month stock price forecast is 19.02, which is an increase of 26.63% from the latest price.

Price Target

$19.02

(26.63% upside)

Analyst Consensus: Buy